A Randomized, Placebo-controlled, Double-blind Study of LY2216684 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.

Trial Profile

A Randomized, Placebo-controlled, Double-blind Study of LY2216684 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Edivoxetine (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 27 Sep 2016 Results of pooled analysis from 4 adjunctive treatment trials and 1 monotherapy trial (n=2561) published in the Journal of Clinical Psychiatry.
    • 01 Mar 2016 Results of pooled analysis of this and other 2 trials (NCT01187407 and NCT01185340) published in the Journal of Clinical Psychiatry
    • 05 Dec 2013 Top-line results published in an Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top